Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18995830 
Collis SJ, et al. (2008) FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Mol Cell 32, 313-24 18995830
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S317-p - Chk1 (human)
Orthologous residues
Chk1 (human): S317‑p, Chk1 (mouse): S317‑p, Chk1 (rat): S317‑p, Chk1 (chicken): S317‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea, aphidicolin increase
siRNA aphidicolin, hydroxyurea CLK2 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FANCM (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FAAP24 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea ATR (human) inhibit treatment-induced increase

T346-p - FANCE (human)
Orthologous residues
FANCE (human): T346‑p, FANCE (mouse): S336‑p, FANCE (rat): S360‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea, aphidicolin increase
siRNA aphidicolin, hydroxyurea CLK2 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FANCM (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FAAP24 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea ATR (human) inhibit treatment-induced increase

S140-p - H2AX (human)
Orthologous residues
H2AX (human): S140‑p, H2AX (mouse): S140‑p, H2AX (rat): S140‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine no change compared to control
siRNA CLK2 (human) increase
roscovitine siRNA CLK2 (human) CLK2 (human) inhibit treatment-induced increase
siRNA FANCM (human) increase
roscovitine siRNA FANCM (human) FANCM (human) inhibit treatment-induced increase
siRNA FAAP24 (human) increase
roscovitine siRNA FAAP24 (human) FAAP24 (human) inhibit treatment-induced increase

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea, aphidicolin increase
siRNA aphidicolin, hydroxyurea CLK2 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FANCM (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea FAAP24 (human) inhibit treatment-induced increase
siRNA aphidicolin, hydroxyurea ATR (human) inhibit treatment-induced increase

T21-p - RFA2 (human)
Orthologous residues
RFA2 (human): T21‑p, RFA2 (mouse): T21‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine no change compared to control
siRNA CLK2 (human) increase
roscovitine siRNA CLK2 (human) CLK2 (human) inhibit treatment-induced increase
siRNA FANCM (human) increase
roscovitine siRNA FANCM (human) FANCM (human) inhibit treatment-induced increase
siRNA FAAP24 (human) increase
roscovitine siRNA FAAP24 (human) FAAP24 (human) inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.